Amedisys (AMED) Expected to Announce Earnings on Wednesday

Amedisys (NASDAQ:AMED - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of $1.39 per share and revenue of $614.61 million for the quarter.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. The firm had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. During the same period in the prior year, the business earned $1.03 EPS. The firm's revenue was up 4.1% on a year-over-year basis. On average, analysts expect Amedisys to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Amedisys Stock Performance

Shares of NASDAQ:AMED traded down $0.01 on Friday, hitting $97.46. The company's stock had a trading volume of 237,080 shares, compared to its average volume of 413,194. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of 35.96, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94. The stock's 50-day moving average is $96.01 and its two-hundred day moving average is $93.73. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.29 and a current ratio of 1.29.

Hedge Funds Weigh In On Amedisys

Several hedge funds and other institutional investors have recently modified their holdings of AMED. AQR Capital Management LLC raised its position in Amedisys by 98.3% in the 1st quarter. AQR Capital Management LLC now owns 13,410 shares of the health services provider's stock valued at $1,242,000 after purchasing an additional 6,646 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of Amedisys during the first quarter worth $214,000. Empowered Funds LLC grew its stake in Amedisys by 10.1% in the first quarter. Empowered Funds LLC now owns 3,854 shares of the health services provider's stock valued at $357,000 after acquiring an additional 354 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Amedisys by 9.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,990 shares of the health services provider's stock valued at $184,000 after acquiring an additional 176 shares during the period. Institutional investors own 94.36% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on AMED. Wall Street Zen lowered Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a research report on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.